Role of alpha 1-blockers in the current management of hypertension

• Main Authors: Li, Hua, Xu, Ting-Yan, Li, Yan, Chia, Yook-Chin, Buranakitjaroen, Peera, Cheng, Hao-Min, Van Huynh, Minh, Sogunuru, Guru Prasad, Tay, Jam Chin, Wang, Tzung-Dau, Kario, Kazuomi, Wang, Ji-Guang
• Format: Article
• Published: Wiley 2022
• Subjects: R Medicine
• Online Access: http://eprints.um.edu.my/41140/

There is emerging evidence that alpha 1-blockers can be safely used in the treatment of hypertension. These drugs can be used in almost all hypertensive patients for blood pressure control. However, there are several special indications. Benign prostatic hyperplasia is a compelling indication of alpha 1-blockers, because of the dual treatment effect on both high blood pressure and lower urinary tract symptoms. Many patients with resistant hypertension would require alpha 1-blockers as add-on therapy. Primary aldosteronism screen is a rapidly increasing clinical demand in the management of hypertension, where alpha 1-blockers are useful for blood pressure control in the preparation for the measurement of plasma aldosterone and renin. Nonetheless, alpha 1-blockers have to be used under several considerations. Among the currently available agents, only long-acting alpha 1-blockers, such as doxazosin gastrointestinal therapeutic system 4-8 mg daily and terazosin 2-4 mg daily, should be chosen. Orthostatic hypotension is a concern with the use of alpha 1-blockers especially in the elderly, and requires careful initial bedtime dosing and avoiding overdosing. Fluid retention is potentially also a concern, which may be overcome by combining an alpha 1-blocker with a diuretic.